NTNeil K. Taunk

Neil K. Taunk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Neil K. Taunk has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Abigail Doucette

    Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania

    2 shared publications
  • Abigail Pepin

    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania

    2 shared publications
  • David A. Mankoff

    Department of Radiology, Division of Nuclear Medicine Imaging and Therapy, University of Pennsylvania, Philadelphia, Pennsylvania

    2 shared publications
  • Freddy E. Escorcia

    Molecular Imaging Branch, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

    2 shared publications
  • Samuel U. Takvorian

    Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania

    2 shared publications
  • Vivek K. Narayan

    Division of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

    2 shared publications

Latest Publications

  • Differential Response to 177 Lu-PSMA-617 in Patients with Tumor Suppressor Gene–Mutated Metastatic Castration-Resistant Prostate Cancer

    by Abigail Pepin, Abigail Doucette, Vivek K. Narayan, Kara N. Maxwell, Samuel U. Takvorian, Sophia R. O’BRien, David A. Mankoff, Philipose G. Mulugeta, Neil K. Taunk

    Genomic alterations are common in metastatic castration-resistant prostate cancer (mCRPC), but limited data exist on the response to 177Lu-PSMA-617 (LuPSMA) in patients with these aberrations. We aimed to characterize oncologic outcomes of patients with mCRPC and germline or somatic aberrations after treatment with LuPSMA. Methods: The medical record was surveyed for all patients with mCRPC treated with LuPSMA between October 2022 and October 2024. All patients who had received at least 1 cycle of LuPSMA and underwent either germline or somatic testing were included. Results: Seventy-two patients were included. Patients with TP53/PTEN/RB1 mutations demonstrated inferior overall survival, even after adjustment for age and race. TP53/PTEN/RB1, BRCA1/2, and CHEK2/PALB2/ATM were not associated with inferior progression-free survival. No individual mutation was significantly associated with changes in the percentage decline in prostate-specific antigen levels from baseline. Conclusion:TP53, PTEN, and RB1 mutations were linked to inferior overall survival in LuPSMA-treated patients and may serve as prognostic biomarkers. Prospective validation is required to establish their predictive value.


  • Safety of the Combination of External Beam Radiotherapy with 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer

    by Abigail Pepin, Abigail Doucette, Neha Vapiwala, Vivek K. Narayan, Samuel U. Takvorian, Sophia R. O’bRien, David A. Mankoff, Philipose Mulugeta, Neil K. Taunk

    The VISION trial of 177Lu-PSMA-617 (LuPSMA) demonstrated improved overall survival in patients with metastatic castration-resistant prostate cancer when compared with the best standard of care. The practice patterns for and safety of the combination of external beam radiotherapy (EBRT) and LuPSMA in the real-world setting are unknown. Here, we characterize the toxicities and efficacy of the combination of EBRT and LuPSMA among patients with metastatic castration-resistant prostate cancer. Methods: The records of all patients treated with LuPSMA at an urban academic institution between 2022 and 2024 were retrospectively extracted from the electronic medical record. Patients were stratified on the basis of their receipt of EBRT. Treatment characteristics of both systemic therapy and EBRT were extracted. Provider-reported toxicities after LuPSMA and EBRT were assessed. Overall survival was assessed using Kaplan–Meier analysis. Results: The records of 113 patients were included in the analysis, including 92 patients who received EBRT and LuPSMA and 21 patients who received LuPSMA alone. The median age was 71.5 and 75 y in the combination therapy and the monotherapy groups, respectively. All patients were heavily pretreated. There were significantly higher rates of prior taxane-based chemotherapy in the combination group compared with those who received LuPSMA alone (92.4% vs. 76.2%; P = 0.045). In total, 207 EBRT courses were delivered among 92 patients. Of these courses, 164 (79.2%) were administered before the start of LuPSMA and 15 (7.2%) occurred between cycles of LuPSMA. Thirty-six patients (39.1%) received periconcurrent LuPSMA (i.e., within 3 mo of receiving EBRT). Most EBRT courses were palliative in intent. There were no significant differences in fatigue, dry eye, and cytopenias after administration of LuPSMA alone compared with periconcurrent LuPSMA and EBRT. There were higher rates of thrombocytopenia (any grade) in patients who received EBRT within 3 mo of LuPSMA relative to those who received EBRT more than 3 mo before LuPSMA (60.6% vs. 34.0%; P = 0.03). The median follow-up was 6.8 mo, during which there were no differences in overall survival between patients treated with prior EBRT relative to those who had never received EBRT (P = 0.10). There were also no differences in overall survival in patients treated with EBRT within 3 mo of LuPSMA relative to those who had never received EBRT (P = 0.10). Conclusion: Receipt of EBRT during or within 3 mo of LuPSMA was not associated with increased toxicity compared with LuPSMA alone and was not associated with receiving fewer cycles of LuPSMA. There were no differences with respect to overall survival between patients who received prior EBRT or EBRT within 3 mo and those who had never received EBRT. Treatment with EBRT in combination with LuPSMA can be incorporated as needed for primarily palliative purposes. Visual Abstract


  • Radiopharmaceuticals for Cancer Diagnosis and Therapy

    by Neil K. Md Taunk, Freddy E. Escorcia, Jason S. Lewis, Lisa Bodei

    Radiopharmaceutical therapy has emerged as a promising approach for the treatment of various cancers. The exploration of novel targets such as tumor-specific antigens, overexpressed receptors, and intracellular biomolecules using antibodies, peptides, or small molecules has expanded the scope of radiopharmaceutical therapy, enabling precise and effective cancer treatment for an increasing number of tumor types. Alpha emitters, characterized by their high linear energy transfer and short path length, offer unique advantages in targeted therapy due to their potent cytotoxicity against cancer cells while sparing healthy tissues. This article reviews recent advancements in identifying novel targets for radiopharmaceutical therapy and applications in utilizing α-emitters for targeted treatment.


  • Top Cited Papers
    Open Access

    Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Radiation Therapy Treatment Planning: A Review of PET Imaging Tracers and Methods to Incorporate PET/CT

    by Jacob Trotter, Austin R. Pantel, Boon-Keng Kevin Teo, Freddy E. Escorcia, Taoran Li, Daniel A. Pryma, Neil K. Taunk


  • Primary Radiation as an Alternative Option for Early-Stage Cervical Cancer

    by Neil K. Taunk, Emma C. Fields, Jeffrey V. Brower